Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATIPUS: Adaptive Platform for Preterm Infants
NCT06461429Not yet recruiting
- Sponsor
- University of Melbourne
- Start
- Nov 2025
- Primary completion
- Dec 2050
- Modality
- Small Molecules
01
Overview
Randomised trial of erythromycin, amoxicillin, azithromycin and caffeine in preterm birth, preterm premature rupture of membranes (pPROM) and apnea of prematurity (AOP) (6 arms), sponsored by University of Melbourne. Primary endpoint: Number of participants who progress by at least one level higher on the PLATIPUS Ordinal Outcome Scale. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
erythromycinamoxicillinazithromycincaffeine
03
Conditions
preterm birthpreterm premature rupture of membranes (pPROM)apnea of prematurity (AOP)
Beyond the preview
Go deeper on NCT06461429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06461429.